TABLE 1.
The demographic parameters for ovarian cancer patients from the TCGA database based on the ADH1B levels.
| Characteristic | Low expression of ADH1B | High expression of ADH1B | P-values |
|---|---|---|---|
| n | 189 | 190 | — |
| FIGO stage, n (%) | — | — | 0.247 |
| Stage I | 1 (0.3%) | 0 (0%) | — |
| Stage II | 13 (3.5%) | 10 (2.7%) | — |
| Stage III | 151 (40.2%) | 144 (38.3%) | — |
| Stage IV | 23 (6.1%) | 34 (9%) | — |
| Primary therapy outcome, n (%) | — | — | 0.511 |
| Progressive disease (PD) | 12 (3.9%) | 15 (4.9%) | — |
| Stable disease (SD) | 9 (2.9%) | 13 (4.2%) | — |
| Partial response (PR) | 19 (6.2%) | 24 (7.8%) | — |
| Complete response (CR) | 114 (37%) | 102 (33.1%) | — |
| Race, n (%) | — | — | 0.289 |
| Asian | 7 (1.9%) | 5 (1.4%) | — |
| Black or African American | 16 (4.4%) | 9 (2.5%) | — |
| White | 160 (43.8%) | 168 (46%) | — |
| Age, n (%) | — | — | 0.015 |
| < =60 | 116 (30.6%) | 92 (24.3%) | — |
| >60 | 73 (19.3%) | 98 (25.9%) | — |
| Histologic grade, n (%) | — | — | 0.051 |
| G1 | 0 (0%) | 1 (0.3%) | — |
| G2 | 16 (4.3%) | 29 (7.9%) | — |
| G3 | 167 (45.3%) | 155 (42%) | — |
| G4 | 1 (0.3%) | 0 (0%) | — |
| Anatomic neoplasm subdivision, n (%) | — | — | 0.011 |
| Unilateral | 63 (17.6%) | 39 (10.9%) | — |
| Bilateral | 118 (33.1%) | 137 (38.4%) | — |
| Venous invasion, n (%) | — | — | 0.100 |
| No | 28 (26.7%) | 13 (12.4%) | — |
| Yes | 32 (30.5%) | 32 (30.5%) | — |
| Lymphatic invasion, n (%) | — | — | 0.023 |
| No | 34 (22.8%) | 14 (9.4%) | — |
| Yes | 50 (33.6%) | 51 (34.2%) | — |
| Tumor residual, n (%) | — | — | 0.015 |
| No residual disease (NRD) | 42 (12.5%) | 25 (7.5%) | — |
| Residual disease (RD) | 121 (36.1%) | 147 (43.9%) | — |
| Tumor status, n (%) | — | — | 0.034 |
| Tumor-free | 45 (13.4%) | 27 (8%) | — |
| With tumor | 126 (37.4%) | 139 (41.2%) | — |
| Age, median (IQR) | 57 (50, 67) | 61 (52, 69.75) | 0.041 |